January 2007
Worldwide Biotech;Jan2007, Vol. 19 Issue 1, p3
Trade Publication
The article reports that the U.S. Food and Drug Administration has designated Pharmaxis' Bronchitol as a fast-track product for cystic fibrosis. The designation is designed to expedite regulatory review of the Bronchitol New Drug Application. According to CEO Alan Robertson, the decision is encouraging news for cystic fibrosis patients.


Related Articles

  • Pharmaxis's product pipeline is progressing well.  // Australasian Biotechnology;Jul2010, Vol. 20 Issue 2, p12 

    The article deals with the achievements of the product pipeline of Pharmaxis as of July 2010. The firm has received the resubmission of its New Drug Application (NDA) for Aridol, a mannitol inhalation powder, in April after the U.S. Food and Drug Administration (FDA) sent a letter in December...

  • FDA licenses cystic fibrosis treatment.  // FDA Consumer;Mar1994, Vol. 28 Issue 2, p2 

    Comments on the licensing of a product by the Food and Drug Administration (FDA) of the first product in 30 years specifically developed to treat cystic fibrosis. Discussion of Dornase alfa, commonly known as DNase; Incidence of cystic fibrosis in America; Genentech Inc. of San Francisco; Side...

  • First antibiotic inhalation approved for cystic fibrosis. Portyansky, Elena // Drug Topics;2/16/98, Vol. 124 Issue 4, p53 

    Reports that the United States Food and Drug Administration has approved tobramycin, an antibiotic inhalation for the treatment of cystic fibrosis. Information from Ralph Sanks of the Cystic Fibrosis Services Pharmacy; Details on nebulized tobramycin; Availability of this product.

  • First DNA-Based Test to Detect Cystic Fibrosis.  // FDA Consumer;Jul/Aug2005, Vol. 39 Issue 4, p4 

    Announces that the U.S. Food & Drug Administration (FDA) has approved the first DNA-based blood test to help detect cystic fibrosis. Information on the Tag-It Cystic Fibrosis Kit; Background of cystic fibrosis.

  • Vertex falls after FDA rejection. Investor's Business Daily // Investors Business Daily;2/5/2016, p0A02 

    The article reports that after the rejection of expansion on the label of its cystic fibrosis drug Kalydeco by the U. S. Food and Drug Administration, biotech company Vertex Pharmaceuticals shares slides down and mention that the company will try to resubmit their application.

  • FDA approved genetic test for cystic fibrosis.  // Infectious Diseases in Children;Oct2009, Vol. 22 Issue 10, p24 

    The article reports on the approval issued by the U.S. Food and Drug Administration for xTAG Cystic Fibrosis Kit from Luminex Molecular Diagnostics.

  • Ivacaftor. Davis, Pamela B.; Yasothan, Uma; Kirkpatrick, Peter // Nature Reviews Drug Discovery;May2012, Vol. 11 Issue 5, p349 

    The article discusses the treatment of cystic fibrosis (CF) through ivacaftor, a small-molecule potentiator of the cystic fibrosis transmembrane conductance regulator (CFTR), which has been approved by the U.S. Food and Drug Administration (FDA) in January 2012. It notes that placebo-controlled...

  • FDA committee gives Pharmaxis tick of approval.  // Australian Life Scientist;11/23/2009, p2 

    Lung function test recommended for approval for us in the U.S. by FDA Pulmonary-Allergy Drugs Advisory Committee.

  • Pharmaxis Seeks FDA Approval for Aridol.  // Bioworld Week;3/9/2009, Vol. 17 Issue 10, p3 

    The article reports on the application filed by Pharmaxis Ltd. to the U.S. Food and Drug Administration for the approval of its Aridol, a bronchial challenge test designed to diagnose the presence of asthma. It states that the drug will be the first dry powder test available in the country, if...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics